|Mr. Johan M. Spoor||Pres, CEO & Director||637.5k||N/A||1972|
|Mr. Maged S. Shenouda M.B.A., R.Ph., R.Ph, MBA||CFO & Director||379.17k||N/A||1964|
|Dr. Mathieu Schué Ph.D.||Head of Laboratory||N/A||N/A||N/A|
|Dr. James E. Pennington||Chief Medical Officer||N/A||N/A||1943|
AzurRx BioPharma, Inc. researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea. The company was incorporated in 2014 and is headquartered in Brooklyn, New York.
AzurRx BioPharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.